233 related articles for article (PubMed ID: 25344360)
21. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
Camidge DR; Skokan M; Kiatsimkul P; Helfrich B; Lu X; Barón AE; Schulte N; Maxson D; Aisner DL; Franklin WA; Doebele RC; Varella-Garcia M
Cancer; 2013 Nov; 119(22):3968-75. PubMed ID: 24022839
[TBL] [Abstract][Full Text] [Related]
22. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
Camidge DR; Theodoro M; Maxson DA; Skokan M; O'Brien T; Lu X; Doebele RC; Barón AE; Varella-Garcia M
Cancer; 2012 Sep; 118(18):4486-94. PubMed ID: 22282074
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
24. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.
Zhang NN; Liu YT; Ma L; Wang L; Hao XZ; Yuan Z; Lin DM; Li D; Zhou YJ; Lin H; Han XH; Sun Y; Shi Y
PLoS One; 2014; 9(1):e84501. PubMed ID: 24404167
[TBL] [Abstract][Full Text] [Related]
25. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
Hembrough T; Liao WL; Hartley CP; Ma PC; Velcheti V; Lanigan C; Thyparambil S; An E; Monga M; Krizman D; Burrows J; Tafe LJ
Clin Chem; 2016 Jan; 62(1):252-61. PubMed ID: 26585927
[TBL] [Abstract][Full Text] [Related]
26. A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material.
Le Quesne J; Maurya M; Yancheva SG; O'Brien M; Popat S; Wotherspoon AC; de Castro DG; Nicholson AG
J Thorac Oncol; 2014 Jun; 9(6):769-74. PubMed ID: 24787965
[TBL] [Abstract][Full Text] [Related]
27. ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues.
Uguen A; Andrieu-Key S; Vergne F; Descourt R; Quéré G; Quintin-Roué I; Key S; Guéguen P; Talagas M; De Braekeleer M; Marcorelles P
Oncol Rep; 2016 Sep; 36(3):1427-34. PubMed ID: 27460205
[TBL] [Abstract][Full Text] [Related]
28. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
[TBL] [Abstract][Full Text] [Related]
29. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
Shan L; Jiang P; Xu F; Zhang W; Guo L; Wu J; Zeng Y; Jiao Y; Ying J
J Thorac Oncol; 2015 Jun; 10(6):e37-9. PubMed ID: 26001147
[No Abstract] [Full Text] [Related]
30. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
31. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas.
Augustin J; Gabignon C; Scriva A; Menu L; Calmel C; Scatton O; Paye F; Fléjou JF; Praz F; Cervera P; Wendum D
Virchows Arch; 2020 Jul; 477(1):33-45. PubMed ID: 32447492
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
[TBL] [Abstract][Full Text] [Related]
33. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
[TBL] [Abstract][Full Text] [Related]
34. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
35. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens].
Wang Z; Wu X; Shi Y; Han X; Cheng G; Li L; Mu X; Zhang Y; Cui D; Zhang L; Fan Z; Zhu G; Ma L; Yang L; Di J; Liu D
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):742-8. PubMed ID: 26813592
[TBL] [Abstract][Full Text] [Related]
36. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
[TBL] [Abstract][Full Text] [Related]
37. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
[TBL] [Abstract][Full Text] [Related]
38. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
[TBL] [Abstract][Full Text] [Related]
39. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]